Rapid and sustained reductions in current suicidal ideation following repeated doses of intravenous ketamine: Secondary analysis of an open-label study

Journal of Clinical Psychiatry

Volumn 77, Issue 6, 2016, Pages e719-e725

  Ionescu, Dawn F ^a,c   Swee, Michaela B ^a   Pavone, Kara J ^a   Taylor, Norman ^a,c   Akeju, Oluwaseun ^a,b   Baer, Lee ^a,c   Nyer, Maren ^a,c   Cassano, Paolo ^a,c   Mischoulon, David ^a,c   Alpert, Jonathan E ^a,c   Brown, Emery N ^a,c   Nock, Matthew K ^b,c   Fava, Maurizio ^a,c   Cusin, Cristina ^a,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD UNIVERSITY   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KETAMINE;

ABNORMAL SENSATION; ADULT; AGED; ARTICLE; BEHAVIOR DISORDER ASSESSMENT; CLINICAL ARTICLE; COLUMBIA SUICIDE SEVERITY RATING SCALE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISSOCIATIVE DISORDER; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DSM-IV; FEMALE; FOLLOW UP; HAMILTON DEPRESSION RATING SCALE; HUMAN; MAJOR DEPRESSION; MALE; OPEN STUDY; PRIORITY JOURNAL; REMISSION; REPEATED DRUG DOSE; SINGLE DRUG DOSE; SUICIDAL IDEATION; TREATMENT RESISTANT DEPRESSION; ADOLESCENT; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DOSE RESPONSE; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; OUTCOME ASSESSMENT; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; PSYCHOMETRY; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; KETAMINE; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; REMISSION INDUCTION; SUICIDAL IDEATION; YOUNG ADULT;

EID: 84976367381     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.15m10056     Document Type: Article

References (39)

1. Preventing suicide: a global imperative. WHO Web site. http://www.who.int/mental-health/suicide-prevention/exe-summary-english.pdfua=1. Updated 2014. Accessed March 21 2016
2. Baca-Garcia E, Perez-Rodriguez MM, Oquendo MA, et al. Estimating risk for suicide attempt: are we asking the right questions' passive suicidal ideation as a marker for suicidal behavior. J Affect Disord. 2011;134(1-3):327-332. doi:10.1016/j.jad.201.06.026
3. -2012 National Strategy for Suicide Prevention: Goals and Objectives for Action. US Department of Health & Human Services Surgeon General's Web site. http://www. surgeongeneral.gov/library/reports/nationalstrategy- suicide-prevention/full-report.pdf. Updated September 2012. Accessed March 21, 2016.
4. Her EH, Mortensen PB, Olesen AV. Mortality and causes of death in a total national sample of patients with affective disorders admitted for the first time between 1973 and 1993. Br J Psychiatry. 2000;176(1):76-82. doi:10.192/bjp.176.1.76
5. Osby U, Brandt L, Correia N, et al. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry. 2001;58(9):844-850. doi:10.101/archpsyc.58.9.84
6. Isomets'E, Henriksson M, Aro H, et al. Suicide in psychotic major depression. J Affect Disord. 1994;31(3):187-191. doi:10.1016/0165-0327(94)9028-0
7. Isomets'ET, Aro HM, Henriksson MM, et al. Suicide in major depression in different treatment settings. J Clin Psychiatry. 1994;55(12):523-527.
8. Guzzetta F, Tondo L, Centorrino F, et al. Lithium treatment reduces suicide risk in recurrent major depressive disorder. J Clin Psychiatry. 2007;68(3):380-383. doi:10.408/JCP.v68n0304
9. Baldessarini RJ, Tondo L, Davis P, et al. Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review. Bipolar Disord. 2006; 8(5 pt 2):625-639. doi:10.1/j.139-5618.206.034.x
10. Meltzer HY, Alphs L, Green AI, et al; International Suicide Prevention Trial Study Group. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry. 2003;60(1):82-91. doi:10.101/archpsyc.60.1.82
11. Fink M, Kellner CH, McCall WV. The role of ECT in suicide prevention. J ECT. 2014;30(1):5-9. doi:10.1097/YCT.0b013e3182a6ad0d
12. Brown GK, Ten Have T, Henriques GR, et al. Cognitive therapy for the prevention of suicide attempts: a randomized controlled trial. JAMA. 2005;294(5):563-570. doi:10.101/jama.294.5.563
13. Griffiths JJ, Zarate CA Jr, Rasimas JJ. Existing and novel biological therapeutics in suicide prevention. Am J Prev Med. 2014;47(suppl 2):S195-S203. doi:10.1016/j.amepre.2014.06.012
14. DiazGranados N, Ibrahim LA, Brutsche NE, et al. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry. 2010;71(12):1605-1611. doi:10.408/JCP.09m05327blu
15. Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856-864. doi:10.101/archpsyc.63.8.856
16. Price RB, Nock MK, Charney DS, et al. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry. 2009;66(5): 522-526. doi:10.1016/j.biopsych.209.04.029
17. Thakurta RG, Das R, Bhattacharya AK, et al. Rapid response with ketamine on suicidal cognition in resistant depression. Indian J Psychol Med. 2012;34(2):170-175. doi:10.4103/0253-7176.101793
18. Zarate CA Jr, Brutsche NE, Ibrahim L, et al. Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry. 2012;71(11):939-946. doi:10.1016/j.biopsych.201.12.010
19. Price RB, Iosifescu DV, Murrough JW, et al. Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression. Depress Anxiety. 2014;31(4):335-343. doi:10.102/da.253
20. Larkin GL, Beautrais AL. A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. Int J Neuropsychopharmacol. 2011;14(8): 1127-1131. doi:10.1017/S146145710629
21. De Gioannis A, De Leo D. Oral ketamine augmentation for chronic suicidality in treatment-resistant depression. Aust N Z J Psychiatry. 2014;48(7):686. doi:10.17/04867414520754
22. Zigman D, Blier P. Urgent ketamine infusion rapidly eliminated suicidal ideation for a patient with major depressive disorder: a case report. J Clin Psychopharmacol. 2013;33(2):270-272. doi:10.1097/JCP.0b013e3182856865
23. aan het Rot M, Collins KA, Murrough JW, et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry. 2010;67(2):139-145. doi:10.1016/j.biopsych.209.08.038
24. Cusin C, Ionescu DF, Pavone KJ, et al. Ketamine augmentation for outpatients with treatmentresistant depression: preliminary evidence for two-step intravenous dose escalation. Aust N Z J Psychiatry. 2016. doi:10.17/0486741631828
25. First MB, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II). Washington, DC: American Psychiatric Press; 1997.
26. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56-62. doi:10.136/jnp.23.1.56
27. Hamilton M. Rating depressive patients. J Clin Psychiatry. 1980;41(12 pt 2):21-24.
28. Chandler GM, Iosifescu DV, Pollack MH, et al. RESEARCH: validation of the Massachusetts General Hospital Antidepressant Treatment History Questionnaire (ATRQ). CNS Neurosci Ther. 2010;16(5):322-325. doi:10.1/j.175-5949.209.0102.x
29. Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168(12):1266-1277. doi:10.176/api.ajp.201.101704
30. Greenwald AG, McGhee DE, Schwartz JL. Measuring individual differences in implicit cognition: the implicit association test. J Pers Soc Psychol. 1998;74(6):1464-1480. doi:10.1037/02-3514.74.6.1464
31. Nock MK, Park JM, Finn CT, et al. Measuring the suicidal mind: implicit cognition predicts suicidal behavior. Psychol Sci. 2010;21(4):511-517. doi:10.17/0956797610364762
32. Bremner JD, Krystal JH, Putnam FW, et al. Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS). J Trauma Stress. 1998;11(1):125-136. doi:10.1023/A:102465317902
33. Bech P. Rating scales in depression: limitations and pitfalls. Dialogues Clin Neurosci. 2006;8(2):207-215.
34. Luckenbaugh DA, Niciu MJ, Ionescu DF, et al. Do the dissociative side effects of ketamine mediate its antidepressant effects? J Affect Disord. 2014;159:56-61. doi:10.1016/j.jad.2014.02.017
35. Cleary P, Guy W. Factor analysis of Hamilton Depression Scale. Drugs Exp Clin Res. 1977;(1):115-120.
36. Ballard ED, Ionescu DF, Vande Voort JL, et al. Improvement in suicidal ideation after ketamine infusion: relationship to reductions in depression and anxiety. J Psychiatr Res. 2014;58:161-166. doi:10.1016/j.jpsychires.2014.07.027
37. Diamond PR, Farmery AD, Atkinson S, et al. Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic. J Psychopharmacol. 2014;28(6): 536-544. doi:10.17/0269814527361
38. Reeves H, Batra S, May RS, et al. Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: a randomized, doubleblind, placebo-controlled pilot study. J Clin Psychiatry. 2008;69(8):1228-1236. doi:10.408/JCP.v69n0805
39. Frye MA, Blier P, Tye SJ. Concomitant benzodiazepine use attenuates ketamine response: implications for large scale study design and clinical development. J Clin Psychopharmacol. 2015;35(3):334-336.